Advertisement
Advertisement

OCUL

OCUL logo

Ocular Therapeutix, Inc.

9.17
USD
Sponsored
+0.26
+2.96%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

9.18

0.00
+0.01%

OCUL Earnings Reports

Positive Surprise Ratio

OCUL beat 18 of 40 last estimates.

45%

Next Report

Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
$16.45M
/
-$0.33
Implied change from Q3 25 (Revenue/ EPS)
+13.11%
/
-13.16%
Implied change from Q4 24 (Revenue/ EPS)
-3.70%
/
+17.86%

Ocular Therapeutix, Inc. earnings per share and revenue

On Nov 04, 2025, OCUL reported earnings of -0.38 USD per share (EPS) for Q3 25, missing the estimate of -0.37 USD, resulting in a -1.60% surprise. Revenue reached 14.54 million, compared to an expected 14.92 million, with a -2.51% difference. The market reacted with a -4.47% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of -0.33 USD, with revenue projected to reach 16.45 million USD, implying an decrease of -13.16% EPS, and increase of 13.11% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Ocular Therapeutix, Inc. reported EPS of -$0.38, missing estimates by -1.6%, and revenue of $14.54M, -2.51% below expectations.
The stock price moved down -4.47%, changed from $11.41 before the earnings release to $10.90 the day after.
The next earning report is scheduled for Mar 02, 2026.
Based on 15 analysts, Ocular Therapeutix, Inc. is expected to report EPS of -$0.33 and revenue of $16.45M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement